Aliases & Classifications for Contact Dermatitis

Summaries for Contact Dermatitis

MalaCards based summary : Contact Dermatitis, also known as contact dermatitis/eczema, is related to nickel allergic contact dermatitis and palladium allergic contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Contact Dermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Glycerol and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hematopoietic system and cellular

Wikipedia : 75 Contact dermatitis is a type of inflammation of the... more...

Related Diseases for Contact Dermatitis

Diseases related to Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 630)
# Related Disease Score Top Affiliating Genes
1 nickel allergic contact dermatitis 34.3 IL5 IL4 IL10 IFNG
2 palladium allergic contact dermatitis 34.2 IL10 CCL17
3 irritant dermatitis 34.1 TNF KRT16 IL1B IL1A FLG
4 toxicodendron dermatitis 33.7 ICAM1 CXCL8
5 dermatitis 31.2 IL5 IL4 IL31 IFNG FLG CCL22
6 ige responsiveness, atopic 31.0 IL5 IL4 IL10 IFNG
7 vasculitis 31.0 TNF SELE ICAM1
8 discoid lupus erythematosus 30.9 KRT16 IL10 FLG
9 latex allergy 30.9 IL5 IL4 FLG
10 alopecia areata 30.8 TNF IL1A IFNG ICAM1
11 leprosy 3 30.8 TNF IL10 IFNG
12 scabies 30.7 IL1A IL10 CXCL8
13 rhinitis 30.6 IL5 IL4 ICAM1 CXCL8
14 folliculitis 30.5 IL5 IL4 IFNG
15 oral lichen planus 30.5 IL1A ICAM1 CXCR3
16 allergic contact dermatitis 30.3 TNF SELE IL5 IL4 IL31 IL1B
17 erythema multiforme 30.2 TNF IFNG ICAM1 CXCR3 CCL17
18 respiratory allergy 30.2 IL5 IL4 IL10
19 allergic hypersensitivity disease 30.1 IL5 IL4 IL10 IFNG CCL22 CCL17
20 milk allergy 30.1 IL5 IL4 IL10
21 severe acute respiratory syndrome 30.1 TNF IFNG CXCL8
22 mycosis fungoides 30.0 IL5 CXCR3 CCL22 CCL17
23 lepromatous leprosy 30.0 TNF IL10 IFNG ICAM1
24 tetanus 30.0 IL5 IL4 IL10 IFNG
25 food allergy 29.9 IL5 IL4 IL10 IFNG FLG
26 crohn's colitis 29.9 TNF IL1B IFNG CXCL8
27 immune deficiency disease 29.9 IL4 IL1A IL10
28 actinic prurigo 29.9 TNF SELE IL1B ICAM1
29 cutaneous t cell lymphoma 29.7 IL4 IFNG CCL17
30 laryngitis 29.7 TNF IL6 IL1B
31 cutaneous lupus erythematosus 29.6 TNF SELE ICAM1 CXCR3
32 stevens-johnson syndrome/toxic epidermal necrolysis 29.6 IL5 IFNG CXCR3 CCL22 CCL17
33 hypereosinophilic syndrome 29.6 IL5 IL4 CCL17
34 fasciitis 29.5 TNF IL6 CXCL8
35 cystitis 29.4 TNF IL6 CXCL8
36 allergic asthma 29.4 IL5 IL4 IL10 IFNG CCL17
37 vaginitis 29.4 IL6 IL1B CXCL8
38 pulpitis 29.4 TNF IL6 IL1B IL1A CXCL8
39 cutaneous leishmaniasis 29.4 TNF IL5 IL4 IL10 IFNG
40 cerebral palsy 29.4 TNF IL6 IL1B
41 idiopathic interstitial pneumonia 29.4 IL4 IFNG ICAM1 CXCL8
42 allergic conjunctivitis 29.3 IL5 IL4 IFNG ICAM1 CXCL8
43 allergic rhinitis 29.3 IL5 IL4 IL10 IFNG ICAM1 CXCL8
44 relapsing-remitting multiple sclerosis 29.3 TNF IL4 IL10 IFNG ICAM1
45 lichen planus 29.2 TNF KRT16 IL4 IFNG ICAM1 FLG
46 pertussis 29.2 TNF IL6 IL1B IL1A IL10
47 hashimoto thyroiditis 29.2 IL4 IFNG ICAM1 CXCR3
48 esophagitis 29.1 IL6 IL5 IL1B CXCL8
49 sarcoidosis 1 29.1 TNF IL1B IFNG CXCR3 CCL17
50 interstitial cystitis 29.1 IL6 CXCR3 CXCL8

Graphical network of the top 20 diseases related to Contact Dermatitis:



Diseases related to Contact Dermatitis

Symptoms & Phenotypes for Contact Dermatitis

UMLS symptoms related to Contact Dermatitis:


pruritus, exanthema

MGI Mouse Phenotypes related to Contact Dermatitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
2 cellular MP:0005384 10.24 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.22 CD4 CXCR3 ICAM1 IFNG IL10 IL1A
4 immune system MP:0005387 10.21 CCL17 CCL22 CD4 CXCR3 ICAM1 IFNG
5 growth/size/body region MP:0005378 10.2 CD4 ICAM1 IFNG IL10 IL1B IL4
6 cardiovascular system MP:0005385 10.16 CXCR3 ICAM1 IFNG IL10 IL1A IL1B
7 digestive/alimentary MP:0005381 10.13 CD4 ICAM1 IFNG IL10 IL4 IL5
8 integument MP:0010771 10.06 CD4 ICAM1 IFNG IL10 IL1A IL1B
9 mortality/aging MP:0010768 9.93 CCL22 CD4 CXCR3 ICAM1 IFNG IL10
10 liver/biliary system MP:0005370 9.8 IFNG IL10 IL4 IL5 IL6 SELE
11 neoplasm MP:0002006 9.61 CXCR3 ICAM1 IFNG IL10 IL1A IL1B
12 respiratory system MP:0005388 9.23 CXCR3 IFNG IL10 IL4 IL5 IL6

Drugs & Therapeutics for Contact Dermatitis

Drugs for Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycerol Approved, Investigational Phase 4 56-81-5 753
2
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
3
Petrolatum Approved, Investigational Phase 4 8009-03-8
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
6
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
7 Dermatologic Agents Phase 4
8 Emollients Phase 4
9 Disinfectants Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Sodium hypochlorite Phase 4
12 Eusol Phase 4
13 Anti-Bacterial Agents Phase 4
14 Anti-Infective Agents Phase 4
15 Antibodies Phase 4
16 Antibodies, Monoclonal Phase 4
17 Immunoglobulins Phase 4
18 Angiogenesis Inhibitors Phase 4
19 Angiogenesis Modulating Agents Phase 4
20
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
21
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
22
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
24
Silver sulfadiazine Approved, Vet_approved Phase 3 22199-08-2 441244
25
Sulfadiazine Approved, Investigational, Vet_approved Phase 3 68-35-9 5215
26
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
27
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
29
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
30
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
31
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
32
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
33
Gemcitabine Approved Phase 3 95058-81-4 60750
34 Coconut Approved Phase 3
35
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 6433735 5283731
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
37
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
38
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
39
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
40
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
41 Neuroprotective Agents Phase 3
42 Methylprednisolone Acetate Phase 3
43 Prednisolone acetate Phase 3
44 Antidotes Phase 3
45 Chelating Agents Phase 3
46 Antitubercular Agents Phase 3
47 Hydroxycholecalciferols Phase 3
48 Anti-Infective Agents, Local Phase 3
49 Hormone Antagonists Phase 3
50 Antiemetics Phase 3

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
2 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
3 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
4 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
5 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride
6 Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents Completed NCT00795951 Phase 4
7 Evaluation of Provase in the Post Burn Rehabilitation Population for Itch Control and Moisturization Properties Completed NCT00782054 Phase 4
8 A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain: A Randomized Control Trial Completed NCT03221946 Phase 4 Diclofenac Sodium;Diclofenac sodium;Diclofenac
9 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed NCT00179959 Phase 4 Sodium hypochlorite (bleach) baths;Mupirocin ointment;Water;Petrolatum Ointment
10 The Effects of Dupilumab on Allergic Contact Dermatitis Not yet recruiting NCT03935971 Phase 4 Dupilumab
11 An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis Not yet recruiting NCT03741933 Phase 4 Apremilast 30mg
12 Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis Unknown status NCT01011621 Phase 3 0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
13 Anti-IL-17 a New Treatment for Contact Dermatititis Unknown status NCT02778711 Phase 3 secukinumab
14 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol Completed NCT00640614 Phase 3
15 A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic Completed NCT02109718 Phase 3 Open Dressings with Petrolatum Jelly;Silver Sulfadiazine Gauze Dressing Group
16 Bio-equivalency Study of the Effects of Vitamin D2 and Vitamin D3 Supplements on 25-hydroxyvitamin D Levels in Exclusively Breast Fed Canadian Infants Completed NCT01190137 Phase 3
17 Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. Recruiting NCT02582177 Phase 3 Candicort®;Nizoral®;Baycuten N®;Canesten®
18 LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Recruiting NCT02973789 Phase 3 Immune checkpoint inhibitors or docetaxel
19 Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
20 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
21 Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents Withdrawn NCT01518348 Phase 3
22 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study Unknown status NCT02028208 Phase 2
23 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
24 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
25 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
26 Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations Completed NCT00612768 Phase 2
27 Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study Completed NCT02028182 Phase 2
28 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
29 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
30 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study Completed NCT00640250 Phase 2
31 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
32 Novel Protective Underglove Completed NCT00170586 Phase 2
33 Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) Recruiting NCT03380026 Phase 2 Triamcinolone;Valchlor 0.016 % Topical Gel
34 Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study Recruiting NCT02615249 Phase 2
35 HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) Recruiting NCT03606590 Phase 2 Sorafenib
36 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
37 A Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Adult Subjects With Moderate to Severe Chronic Allergic Contact Dermatitis Not yet recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
38 Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy and Oral Minoxidil Not yet recruiting NCT04011748 Phase 2
39 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
40 Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). Completed NCT01529320 Phase 1 Adventan® (methylprednisolone aceponate 0,1%)
41 Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial Completed NCT00614289 Phase 1
42 A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone Completed NCT03089775 Phase 1 BBI-2000;Vehicle
43 A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers Completed NCT02700373 Phase 1 PDC-APB;Placebo
44 A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers Completed NCT03375957 Phase 1 ATx201;ATx201 Placebo Gel
45 A Phase I Study of the Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1 Completed NCT03661541 Phase 1 Squaric Acid Dibutyl Ester
46 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
47 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
48 Bariederm Cream in Chronic Contact Dermatitis Unknown status NCT02026700
49 Dermatologically Tested - Patch Tests - to Assess the Irritancy/Allergic Sensitivity of the Natural Personal-care Products Developed by "Mother's Choice". Unknown status NCT01816542
50 Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis Unknown status NCT01311986

Search NIH Clinical Center for Contact Dermatitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aloe Vera Leaf
Bendazac
Clioquinol
Cortisone acetate
Dexamethasone
Hydrocortisone
Methylprednisolone
pramoxine
Pramoxine hydrochloride
Prednisolone
Prednisone
Quaternium-18
Triamcinolone

Cochrane evidence based reviews: dermatitis, contact

Genetic Tests for Contact Dermatitis

Anatomical Context for Contact Dermatitis

MalaCards organs/tissues related to Contact Dermatitis:

41
Skin, Testes, T Cells, Lymph Node, Eye, Breast, Monocytes

Publications for Contact Dermatitis

Articles related to Contact Dermatitis:

(show top 50) (show all 12890)
# Title Authors PMID Year
1
Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. 9 38
19538184 2009
2
Protein contact dermatitis: allergens, pathogenesis, and management. 9 38
18845114 2008
3
Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. 9 38
18637008 2008
4
Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. 9 38
18416755 2008
5
Allergies in India: an analysis of 3389 patients attending an allergy clinic in Mumbai, India. 9 38
18828339 2008
6
Allergic contact dermatitis from natural rubber latex in atopic dermatitis and the risk of later Type I allergy. 9 38
15982232 2005
7
Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. 9 38
15059180 2004
8
Expression of CS-1 fibronectin precedes monocyte chemoattractant protein-1 production during elicitation of allergic contact dermatitis. 9 38
12911787 2003
9
Nickel-induced cytokine production from mononuclear cells in nickel-sensitive individuals and controls. Cytokine profiles in nickel-sensitive individuals with nickel allergy-related hand eczema before and after nickel challenge. 9 38
10929769 2000
10
Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. 9 38
10651994 2000
11
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 9 38
10504443 1999
12
Chromium induced contact dermatitis and indices for diagnosis. 9 38
17219860 1999
13
Keratin 17 is expressed during the course of SLS-induced irritant contact dermatitis, but unlike keratin 16, the degree of expression is unrelated to the density of dividing keratinocytes. 9 38
9686973 1998
14
In vivo cytokine profiles in allergic and irritant contact dermatitis. 9 38
8654078 1995
15
Cell-bound IgE and increased expression of Fc epsilon-receptors on dendritic cells in cutaneous infiltrates of mycosis fungoides. 9 38
1834378 1991
16
Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease. 38
31195861 2019
17
The effects of para-phenylenediamine (PPD) on the skin fibroblast cells. 38
30474463 2019
18
Microfluidics-based skin irritation test using in vitro 3D angiogenesis platform. 38
31431937 2019
19
Airborne contact dermatitis apparently acquired as a result of using pericarp juice from an Indian marking nut as a home remedy to treat patchy hair loss. 38
30907003 2019
20
Role of TRPA1 receptors in skin inflammation induced by volatile chemical irritants in mice. 38
31228448 2019
21
Contact sensitivity to textile dyes in patients with pigmented purpuric dermatosis. 38
30843744 2019
22
Postoperative purpuric contact dermatitis: Think about antiseptics. 38
30919977 2019
23
Allergic contact dermatitis caused by oxidized linalool in a deodorant. 38
30912148 2019
24
Dermatology ECHO: A case presentation demonstrating benefits of specialty telementoring in primary care. 38
29933723 2019
25
Skin Complications Associated With Pediatric Central Venous Access Devices: Prevalence, Incidence, and Risk. 38
31104548 2019
26
Evaluation of in vitro testing strategies for hazard assessment of the skin sensitization potential of "real-life" mixtures: The case of henna-based hair-colouring products containing p-phenylenediamine. 38
31006869 2019
27
Adding sorbitan sesquioleate to the European baseline series: Necessary, reasonable, or unavoidable? 38
31177535 2019
28
Spinal IL-33/ST2 signaling mediates chronic itch in mice through the astrocytic JAK2-STAT3 cascade. 38
31087583 2019
29
αEβ7 Expression Increases With the Extent of Cutaneous Involvement in Mycosis Fungoides. 38
30839339 2019
30
Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients. 38
31206704 2019
31
Artificial nail wearing: Unexpected elicitor of allergic contact dermatitis, oral lichen planus and risky arthroplasty. 38
30793321 2019
32
Allergic contact dermatitis by isobornyl acrylate in glucose monitoring devices: Report of two cases. 38
31281970 2019
33
Dermatitis among workers in Ontario: results from the Occupational Disease Surveillance System. 38
31320492 2019
34
Allergic contact dermatitis caused by synthetic rubber gloves in healthcare workers: Sensitization to 1,3-diphenylguanidine is common. 38
30891769 2019
35
All-trans-retinoic acid activated mast cells via Mas-related G-protein-coupled receptor-X2 in retinoid dermatitis. 38
31006867 2019
36
Hydrogel containing silibinin nanocapsules presents effective anti-inflammatory action in a model of irritant contact dermatitis in mice. 38
31238095 2019
37
Allergic contact dermatitis caused by isobornyl acrylate in the Enlite glucose sensor and the Paradigm MiniMed Quick-Set insulin infusion set. 38
31385313 2019
38
[Prevention of hand eczema]. 38
31410496 2019
39
Tandem repeated irritation test (TRIT) studies and clinical relevance: Post 2006. 38
29886752 2019
40
Patch Test Results and Outcome in Patients with Complications from Total Knee Arthroplasty: A Consecutive Case Series. 38
31434145 2019
41
Etiological Contact Allergen Chemical Identification and Confirmation. 38
31433381 2019
42
Important New Fragrance Allergens. II. Limonene Hydroperoxides. 38
31433385 2019
43
Contact Allergy to and Other Adverse Effects of Fragrances: A Brief Overview. 38
31433384 2019
44
Cytoimmunofluorescence Diagnosis in Surgically Induced Pemphigus Foliaceus. 38
31335412 2019
45
Contact dermatitis caused by the traditional Chinese medicine Gynura segetum. 38
31373023 2019
46
Oleylamine-induced pustular irritant contact dermatitis. 38
31389016 2019
47
Highlights in allergic contact dermatitis 2018/2019. 38
31145193 2019
48
Occupational allergic contact dermatitis from systemic drugs. 38
31400016 2019
49
Contact allergen (PPD and DNCB)-induced keratinocyte sensitization is partly mediated through a low molecular weight hyaluronan (LMWHA)/TLR4/NF-κB signaling axis. 38
31226360 2019
50
Epidemiology and Comorbidities of Psoriasis among Israeli Adolescents: A Large Cross-Sectional Study. 38
31390627 2019

Variations for Contact Dermatitis

Expression for Contact Dermatitis

Search GEO for disease gene expression data for Contact Dermatitis.

Pathways for Contact Dermatitis

Pathways related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF IL6 IL5 IL4 IL31 IL1B
2
Show member pathways
13.96 TNF IL6 IL5 IL4 IL1B IL1A
3
Show member pathways
13.82 TNF IL6 IL5 IL4 IL31 IL1B
4
Show member pathways
13.69 TNF IL6 IL5 IL4 IL1B IL1A
5
Show member pathways
13.57 TNF IL6 IL5 IL4 IL1B IL1A
6
Show member pathways
13.48 TNF IL6 IL5 IL4 IL31 IL1B
7
Show member pathways
13.47 TNF IL6 IL5 IL4 IL1B IL1A
8
Show member pathways
13.17 TNF IL6 IL1B IL10 IFNG CXCL8
9
Show member pathways
13.03 TNF IL6 IL1B ICAM1 CXCL8 CD4
10
Show member pathways
13.02 TNF IL6 IL5 IL4 IL1B IL1A
11
Show member pathways
12.92 CXCR3 CXCL8 CD4 CCL22 CCL17
12 12.89 IL6 IL5 IL4 IFNG CXCL8
13
Show member pathways
12.83 TNF IL6 IL1B IFNG CXCL8
14
Show member pathways
12.8 TNF IL6 IL5 IL4 IL1B IL1A
15
Show member pathways
12.75 TNF IL1B IL1A IFNG CD4
16
Show member pathways
12.73 TNF IL6 IL1B IL10 IFNG CD4
17
Show member pathways
12.72 TNF IL6 IL5 IL4 IL1B IL1A
18
Show member pathways
12.71 TNF IL4 IL10 IFNG CD4
19 12.66 TNF IL4 IL1B IL10 IFNG
20
Show member pathways
12.55 TNF IL6 IL5 IL4 IL1B IFNG
21
Show member pathways
12.54 TNF IL4 IFNG ICAM1
22
Show member pathways
12.51 TNF IL6 IL4 IL1B IFNG ICAM1
23
Show member pathways
12.5 IL6 IL5 IL4 IL10 IFNG
24
Show member pathways
12.48 TNF IL6 IL1B IL1A IFNG CXCL8
25
Show member pathways
12.46 TNF IL6 IL5 IL4 IL1B IL1A
26
Show member pathways
12.44 TNF IL4 IL1B IL1A IL10 IFNG
27 12.42 TNF IL6 IL1B IL1A IL10 IFNG
28
Show member pathways
12.4 TNF IL6 IL1B IL10 CCL22 CCL17
29
Show member pathways
12.37 CXCR3 CXCL8 CCL22 CCL17
30
Show member pathways
12.37 TNF IL6 IL1B IL1A CXCL8
31
Show member pathways
12.37 IL1B IL1A ICAM1 CXCR3 CXCL8 CCL22
32
Show member pathways
12.37 TNF IL6 IL4 IL1B IFNG CXCL8
33 12.36 TNF IL6 IL1B IL1A IL10 CXCL8
34
Show member pathways
12.34 TNF IL6 IL1A CXCL8
35
Show member pathways
12.29 TNF IL1B IL1A IFNG
36 12.29 TNF SELE IL1B IL1A IFNG ICAM1
37
Show member pathways
12.26 TNF IL6 IL1B IL10 IFNG CD4
38 12.24 TNF IL6 IL5 IL4 IL10 IFNG
39
Show member pathways
12.21 TNF IL6 IL4 IL1B IFNG
40 12.19 TNF IL6 IL4 IL1B IL1A IFNG
41 12.15 TNF IL1B IL1A IFNG
42 12.15 TNF SELE IL6 IL1B ICAM1
43 12.15 TNF IL6 IL1B IL10 IFNG CXCL8
44 12.14 TNF SELE IL6 IL1B IL1A ICAM1
45 12.12 IL6 IL1B IL1A IFNG CXCL8
46 12.11 TNF IL6 IL5 IL4 IL1B IL1A
47
Show member pathways
12.09 IL4 IL1B IFNG CD4
48 12.09 TNF IL6 IL1B IL1A IFNG ICAM1
49 12.04 TNF IL1B ICAM1 CXCL8
50 12.03 SELE IL6 IL5 IL4 IFNG ICAM1

GO Terms for Contact Dermatitis

Cellular components related to Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF IL6 IL5 IL4 IL31 IL1B
2 extracellular space GO:0005615 9.47 TNF SELE IL6 IL5 IL4 IL31
3 membrane raft GO:0045121 9.46 TNF SELE ICAM1 CD4

Biological processes related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.99 TNF SELE IL1B ICAM1
2 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL1B IFNG CD4
3 response to lipopolysaccharide GO:0032496 9.97 SELE IL1B IL10 ICAM1
4 chemotaxis GO:0006935 9.97 CXCR3 CXCL8 CCL22 CCL17
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF IL6 IL1B ICAM1
6 inflammatory response GO:0006954 9.93 TNF SELE KRT16 IL6 IL5 IL1B
7 cellular response to tumor necrosis factor GO:0071356 9.92 ICAM1 CXCL8 CCL22 CCL17
8 cellular response to interferon-gamma GO:0071346 9.9 ICAM1 CCL22 CCL17
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.9 IL6 IL5 ICAM1 CD4
10 calcium-mediated signaling GO:0019722 9.89 SELE CXCR3 CXCL8
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IL6 IL4 IFNG
12 neutrophil chemotaxis GO:0030593 9.89 IL1B CXCL8 CCL22 CCL17
13 regulation of insulin secretion GO:0050796 9.88 TNF IL1B IFNG
14 cellular response to interleukin-1 GO:0071347 9.88 ICAM1 CXCL8 CCL22 CCL17
15 positive regulation of interleukin-6 production GO:0032755 9.87 TNF IL6 IL1B
16 humoral immune response GO:0006959 9.86 TNF IL6 IFNG
17 chemokine-mediated signaling pathway GO:0070098 9.85 CXCR3 CXCL8 CCL22 CCL17
18 monocyte chemotaxis GO:0002548 9.84 IL6 CCL22 CCL17
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 TNF ICAM1 CD4 CCL22 CCL17
20 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.82 TNF IL1B IL1A
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 IL4 IL10 ICAM1
22 positive regulation of DNA-binding transcription factor activity GO:0051091 9.8 TNF IL6 IL5 IL1B IL10
23 positive regulation of cytokine secretion GO:0050715 9.79 TNF IL1A IL10
24 negative regulation of neurogenesis GO:0050768 9.78 TNF IL6 IL1B
25 positive regulation of T cell proliferation GO:0042102 9.78 IL6 IL4 IL1B CD4
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 TNF IL1B IFNG ICAM1
27 positive regulation of glial cell proliferation GO:0060252 9.74 TNF IL6 IL1B
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 TNF IL1B IFNG
29 cellular response to lipopolysaccharide GO:0071222 9.73 TNF IL6 IL1B IL10 ICAM1 CXCL8
30 cytokine-mediated signaling pathway GO:0019221 9.73 TNF IL6 IL5 IL4 IL31 IL1B
31 response to molecule of bacterial origin GO:0002237 9.72 IL10 CXCL8
32 positive regulation of podosome assembly GO:0071803 9.72 TNF IL5
33 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL6 IL5
34 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
35 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TNF IL1B
36 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 TNF IL1B IL10
38 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL4 IL10
40 ectopic germ cell programmed cell death GO:0035234 9.7 IL1B IL1A
41 response to glucocorticoid GO:0051384 9.7 TNF IL6 IL10
42 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.68 TNF ICAM1
43 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 TNF IL10
44 positive regulation of fever generation GO:0031622 9.68 TNF IL1B
45 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.67 IL1B IL1A CD4
46 type 2 immune response GO:0042092 9.66 IL4 IL10
47 sequestering of triglyceride GO:0030730 9.66 TNF IL1B
48 regulation of isotype switching GO:0045191 9.65 IL4 IL10
49 receptor biosynthetic process GO:0032800 9.63 TNF IL10
50 fever generation GO:0001660 9.63 IL1B IL1A

Molecular functions related to Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.4 TNF IL6 IL5 IL4 IL31 IL1B
2 chemokine activity GO:0008009 9.33 CXCL8 CCL22 CCL17
3 interleukin-1 receptor binding GO:0005149 9.26 IL1B IL1A
4 growth factor activity GO:0008083 9.26 IL6 IL5 IL4 IL10

Sources for Contact Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....